Abstract:Rare diseases pose immense challenges for healthcare systems due to their low prevalence, associated disabilities, and attendant treatment costs. Advancements in gene therapy, such as treatments for Spinal Muscular Atrophy (SMA), have introduced novel therapeutic options, but the high costs, exemplified by Zolgensma® at US$2.1 million, present significant financial barriers. This scoping review aimed to compare the funding approaches for rare disease treatments across high-performing health systems in Australia, Singapore, South Korea, the United Kingdom (UK), and the United States (US), aiming to identify best practices and areas for future research.

What problem does this paper attempt to address?

The paper primarily explores the funding strategies and policies for rare disease treatments in five high-income countries (Australia, Singapore, South Korea, the United Kingdom, and the United States) and attempts to identify best practices and future research directions. ### Research Background - **Challenges of Rare Diseases**: Rare diseases pose significant challenges to healthcare systems due to their low prevalence, associated disabilities, and high treatment costs. - **Development of Gene Therapies**: Advances in treatments, such as for spinal muscular atrophy (SMA), have introduced new therapeutic methods, but the high costs (e.g., the price of Zolgensma® reaching $2.1 million) have become major financial barriers. ### Research Objectives - Compare the funding approaches for rare disease treatments in these five high-income countries. - Aim to identify best practices and key areas for future research. ### Methods - Literature search conducted according to PRISMA-ScR guidelines and the methodological framework of Arksey and O'Malley. - Databases such as Medline, EMBASE, and Cochrane were searched, along with grey literature from national health department websites and leading national organizations focused on rare diseases. - The study focused on literature published between 2010 and 2024, covering drug approval processes, reimbursement decisions, and funding mechanisms. ### Key Findings - Australia utilizes the Life Saving Drugs Program and risk-sharing agreements. - Singapore relies on the Rare Disease Fund, which is matched with public donations. - South Korea's National Health Insurance Service covers specific orphan drugs through risk-sharing agreements. - The United Kingdom relies on the National Institute for Health and Care Excellence (NICE) to assess the cost-effectiveness of treatments, supported by the Innovative Medicines Fund. - The United States combines federal and state programs, private insurance, and nonprofit support. ### Conclusion - Risk-sharing agreements provide practical solutions for managing the financial pressures of expensive treatments. - These agreements link payments to actual treatment outcomes, helping to distribute financial risk and promote ongoing data collection. - Countries should consider adopting and expanding these agreements to balance short-term expenditures with long-term benefits, ensuring equitable access to critical treatments for rare disease patients.

Comparative policy analysis of national rare disease funding policies in Australia, Singapore, South Korea, the United Kingdom and the United States: a scoping review

Review of 11 national policies for rare diseases in the context of key patient needs

A Cross-National Comparative Study of Orphan Drug Policies in the United States, the European Union, and Japan: Towards a Made-in-china Orphan Drug Policy.

Orphan drug policy analysis in China

Analysis of affordability differences for rare diseases in China: a comparison across disease types and regions

Pharmaceutical policy and innovation for rare diseases: A narrative review

RO2 ASSESSING THE RELATIONSHIP BETWEEN LIFELONG VALUE AND PRICING FOR ORPHAN DRUGS IN ULTRA-RARE DISEASES

Rare Disease Centers for Periodic Paralysis: China Versus the United States and United Kingdom

Patient access schemes in Asia-pacific markets: current experience and future potential

Accessibility Of Drugs For Rare Diseases In China: Policies And Current Situation

The next generation of rare disease drug policy: ensuring both innovation and affordability

The availability and affordability of orphan drugs for rare diseases in China

[Authorization and reimbursement of orphan drugs in an international comparison]

Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications

Overview on social security system of rare diseases in China.

Federal Funding for Expensive Drugs for Rare Diseases: How Do We Pick and Choose?

Investigation of the diagnostic importance and accuracy of CT in the chest compared to the RT-PCR test for suspected COVID-19 patients in Jordan

Research on the health security policy of rare diseases at home and abroad

Socio-economic costs of rare diseases and the risk of financial hardship: a cross-sectional study

Does Cost-Effectiveness Analysis Overvalue Potential Cures? Exploring Alternative Methods for Applying a "Shared Savings" Approach to Cost Offsets

A systematic review of economic evaluations of orphan medicines for the management of spinal muscular atrophy